JOM KITA KE POLITEKNIK

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer (Record no. 296)

MARC details
042 ## - AUTHENTICATION CODE
Authentication code dc
100 10 - MAIN ENTRY--PERSONAL NAME
Personal name Xia, Youli
Relator term author
9 (RLIN) 1280
245 00 - TITLE STATEMENT
Title Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. American Association for Cancer Research,
Date of publication, distribution, etc. 2022-08-15.
500 ## - GENERAL NOTE
General note /pmc/articles/PMC7613305/
500 ## - GENERAL NOTE
General note /pubmed/35653148
520 ## - SUMMARY, ETC.
Summary, etc. PURPOSE: Endocrine therapy resistance (ETR) remains the greatest challenge in treating patients with hormone receptor-positive breast cancer. We set out to identify molecular mechanisms underlying ETR through in-depth genomic analysis of breast tumors. EXPERIMENTAL DESIGN: We collected pre-treatment and sequential on-treatment tumor samples from 35 patients with estrogen receptor-positive breast cancer treated with neoadjuvant then adjuvant endocrine therapy; 3 had intrinsic resistance, 19 acquired resistance, and 13 remained sensitive. Response was determined by changes in tumor volume neoadjuvantly and by monitoring for adjuvant recurrence. Twelve patients received two or more lines of endocrine therapy, with subsequent treatment lines being initiated at the time of development of resistance to the previous endocrine therapy. DNA whole-exome sequencing and RNA sequencing were performed on all samples, totalling 169 unique specimens. DNA mutations, copy-number alterations, and gene expression data were analyzed through unsupervised and supervised analyses to identify molecular features related to ETR. RESULTS: Mutations enriched in ETR included ESR1 and GATA3. The known ESR1 D538G variant conferring ETR was identified, as was a rarer E380Q variant that confers endocrine hypersensitivity. Resistant tumors which acquired resistance had distinct gene expression profiles compared with paired sensitive tumors, showing elevated pathways including ER, HER2, GATA3, AKT, RAS, and p63 signaling. Integrated analysis in individual patients highlighted the diversity of ETR mechanisms. CONCLUSIONS: The mechanisms underlying ETR are multiple and characterized by diverse changes in both somatic genetic and transcriptomic profiles; to overcome resistance will require an individualized approach utilizing genomic and genetic biomarkers and drugs tailored to each patient.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction ©2022 The Authors; Published by the American Association for Cancer Research
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
546 ## - LANGUAGE NOTE
Language note en
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element Translational Cancer Mechanisms and Therapy
9 (RLIN) 1292
655 7# - INDEX TERM--GENRE/FORM
Genre/form data or focus term Text
Source of term local
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name He, Xiaping
Relator term author
9 (RLIN) 1281
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Renshaw, Lorna
Relator term author
9 (RLIN) 1282
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Martinez-Perez, Carlos
Relator term author
9 (RLIN) 1283
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Kay, Charlene
Relator term author
9 (RLIN) 1284
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Gray, Mark
Relator term author
9 (RLIN) 1285
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Meehan, James
Relator term author
9 (RLIN) 1286
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Parker, Joel S.
Relator term author
9 (RLIN) 1287
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Perou, Charles M.
Relator term author
9 (RLIN) 1288
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Carey, Lisa A.
Relator term author
9 (RLIN) 1289
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Dixon, J. Michael
Relator term author
9 (RLIN) 1290
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Turnbull, Arran
Relator term author
9 (RLIN) 1291
786 0# - DATA SOURCE ENTRY
Note Clin Cancer Res
856 41 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.1158/1078-0432.CCR-21-3189">http://dx.doi.org/10.1158/1078-0432.CCR-21-3189</a>
Public note Connect to this object online.

No items available.